Search Results - "Johnson, Peter W.M."

Conformation of the Human Immunoglobulin G2 Hinge Imparts Superagonistic Properties to Immunostimulatory Anticancer Antibodies by White, Ann L., Chan, H.T. Claude, French, Ruth R., Willoughby, Jane, Mockridge, C. Ian, Roghanian, Ali, Penfold, Christine A., Booth, Steven G., Dodhy, Ali, Polak, Marta E., Potter, Elizabeth A., Ardern-Jones, Michael R., Verbeek, J. Sjef, Johnson, Peter W.M., Al-Shamkhani, Aymen, Cragg, Mark S., Beers, Stephen A., Glennie, Martin J.

“…Monoclonal antibody (mAb) drugs that stimulate antitumor immunity are transforming cancer treatment but require optimization for maximum clinical impact. Here,…”
Get full text

Primary mediastinal large B-cell lymphoma by Martelli, Maurizio, Ferreri, Andrés, Di Rocco, Alice, Ansuinelli, Michela, Johnson, Peter W.M

“…Abstract Primary mediastinal large B-cell lymphoma (PMLBCL) is a distinct clinical and biological disease from other types of DLBCL. It is more frequent in…”
Get full text

S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition by Hayden, Annette, Johnson, Peter W. M., Packham, Graham, Crabb, Simon J.

“…Epigenetic abnormalities including abnormal histone methyltransferase activity contribute to breast cancer pathogenesis. An example is over expression of the…”
Get full text

The Dual Syk/JAK Inhibitor Cerdulatinib Antagonizes B-cell Receptor and Microenvironmental Signaling in Chronic Lymphocytic Leukemia by Blunt, Matthew D, Koehrer, Stefan, Dobson, Rachel C, Larrayoz, Marta, Wilmore, Sarah, Hayman, Alice, Parnell, Jack, Smith, Lindsay D, Davies, Andrew, Johnson, Peter W M, Conley, Pamela B, Pandey, Anjali, Strefford, Jonathan C, Stevenson, Freda K, Packham, Graham, Forconi, Francesco, Coffey, Greg P, Burger, Jan A, Steele, Andrew J

“…B-cell receptor (BCR)-associated kinase inhibitors, such as ibrutinib, have revolutionized the treatment of chronic lymphocytic leukemia (CLL). However, these…”
Get full text

Anti-CD20 monoclonal antibodies: historical and future perspectives by LIM, Sean H, BEERS, Stephen A, FRENCH, Ruth R, JOHNSON, Peter W. M, GLENNIE, Martin J, CRAGG, Mark S

“…Antibodies to CD20 have confirmed the hypothesis that monoclonal reagents can be given in vivo to alleviate human diseases. The targeting of CD20 on normal,…”
Get full text

Treatment of advanced-stage Hodgkin lymphoma by Vassilakopoulos, Theodoros P, Johnson, Peter W.M

“…Abstract There is now good evidence that the escalated BEACOPP regimen (bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine,…”
Get full text

Augmentation of CD134 (OX40)-dependent NK anti-tumour activity is dependent on antibody cross-linking by Turaj, Anna H., Cox, Kerry L., Penfold, Christine A., French, Ruth R., Mockridge, C. Ian, Willoughby, Jane E., Tutt, Alison L., Griffiths, Jordana, Johnson, Peter W. M., Glennie, Martin J., Levy, Ronald, Cragg, Mark S., Lim, Sean H.

“…CD134 (OX40) is a member of the tumour necrosis factor receptor superfamily (TNFRSF). It acts as a costimulatory receptor on T cells, but its role on NK cells…”
Get full text

Randomized Comparison of the Stanford V Regimen and ABVD in the Treatment of Advanced Hodgkin's Lymphoma: United Kingdom National Cancer Research Institute Lymphoma Group Study ISRCTN 64141244 by HOSKIN, Peter J, LOWRY, Lisa, PETTITT, Andrew, CUNNINGHAM, David, PETTENGELL, Ruth, SWEETENHAM, John, LINCH, David, JOHNSON, Peter W. M, HORWICH, Alan, JACK, Andrew, MEAD, Ben, HANCOCK, Barry W, SMITH, Paul, WENDI QIAN, PATRICK, Philippa, POPOVA, Bilyana

“…This multicenter, prospective, randomized controlled trial compared the efficacy and toxicity of two chemotherapy regimens in advanced Hodgkin's lymphoma (HL):…”
Get full text

Rituximab, cyclophosphamide, doxorubicin, vincristine and prednisolone (R‐CHOP) in the management of primary mediastinal B‐cell lymphoma: a subgroup analysis of the UK NCRI R‐CHOP 14 versus 21 trial by Gleeson, Mary, Hawkes, Eliza A., Cunningham, David, Chadwick, Nick, Counsell, Nicholas, Lawrie, Anthony, Jack, Andrew, Smith, Paul, Mouncey, Paul, Pocock, Christopher, Ardeshna, Kirit M., Radford, John, McMillan, Andrew, Davies, John, Turner, Deborah, Kruger, Anton, Johnson, Peter W.M., Gambell, Joanna, Linch, David

“…Summary We performed a subgroup analysis of the phase III UK National Cancer Research Institute R‐CHOP‐14 versus R‐CHOP‐21 (two‐ versus three‐weekly rituximab,…”
Get full text

Consolidation Radiotherapy in Patients With Advanced Hodgkin's Lymphoma: Survival Data From the UKLG LY09 Randomized Controlled Trial (ISRCTN97144519) by JOHNSON, Peter W. M, SYDES, Matthew R, HANCOCK, Barry W, CULLEN, Michael, RADFORD, John A, STENNING, Sally P

“…This study analyzed the outcomes of nonrandomized consolidation radiotherapy (RT) given after chemotherapy in the initial treatment of advanced Hodgkin's…”
Get full text

Short duration immunochemotherapy followed by radioimmunotherapy consolidation is effective and well tolerated in relapsed follicular lymphoma: 5‐year results from a UK National Cancer Research Institute Lymphoma Group study by Illidge, Tim M., McKenzie, Hayley S., Mayes, Sam, Bates, Andrew, Davies, Andrew J., Pettengell, Ruth, Stanton, Louise, Cozens, Kelly, Hampson, Grace, Dive, Caroline, Zivanovic, Maureen, Tipping, Jill, Gallop‐Evans, Eve, Radford, John A., Johnson, Peter W.M.

“…Summary We report a phase II study to evaluate the efficacy and toxicity of abbreviated immunochemotherapy followed by 90Y Ibritumomab tiuxetan (90Y‐IT) in…”
Get full text

The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial by Rule, Simon, Smith, Paul, Johnson, Peter W M, Bolam, Simon, Follows, George, Gambell, Joanne, Hillmen, Peter, Jack, Andrew, Johnson, Stephen, Kirkwood, Amy A, Kruger, Anton, Pocock, Christopher, Seymour, John F, Toncheva, Milena, Walewski, Jan, Linch, David

“…Mantle cell lymphoma is an incurable and generally aggressive lymphoma that is more common in elderly patients. Whilst a number of different chemotherapeutic…”
Get full text

Maximum tumor diameter is associated with event-free survival in PET-negative patients with stage I/IIA Hodgkin lymphoma by Illidge, Tim M., Phillips, Elizabeth H., Counsell, Nicholas, Pettengell, Ruth, Johnson, Peter W.M., Culligan, Dominic J., Popova, Bilyana, Clifton-Hadley, Laura, McMillan, Andrew, Hoskin, Peter, Barrington, Sally F., Radford, John

“…•Baseline maximum tumor diameter is an important predictor of relapse for patients with ES-HL achieving complete metabolic remission.•Patients with baseline…”
Get full text

Primary mediastinal B-cell lymphoma by Johnson, Peter W M, Davies, Andrew J

“…Primary mediastinal B-cell lymphoma is a discrete clinicopathologic entity. Molecular analysis reveals it to be distinct from other types of large B-cell…”
Get full text

Comparison of ABVD and Alternating or Hybrid Multidrug Regimens for the Treatment of Advanced Hodgkin's Lymphoma: Results of the United Kingdom Lymphoma Group LY09 Trial (ISRCTN97144519) by JOHNSON, Peter W. M, RADFORD, John A, RYDER, David, HANCOCK, Barry W, CULLEN, Michael H, SYDES, Matthew R, WALEWSKI, Jan, JACK, Andrew S, MACLENNAN, Kenneth A, STENNING, Sally P, CLAWSON, Simon, SMITH, Paul

“…To perform an open-label, randomized, controlled trial comparing treatment with doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) with two multidrug…”
Get full text

Current strategies to target the anti-apoptotic Bcl-2 protein in cancer cells by Osford, Sara M E, Dallman, Claire L, Johnson, Peter W M, Ganesan, A, Packham, Graham

“…Apoptosis (or programmed cell death) is a genetically controlled "cell suicide" pathway which plays an essential role in deleting excess, unwanted or damaged…”
Get more information

Risk prediction of covid-19 related death and hospital admission in adults after covid-19 vaccination: national prospective cohort study by Hippisley-Cox, Julia, Coupland, Carol Ac, Mehta, Nisha, Keogh, Ruth H, Diaz-Ordaz, Karla, Khunti, Kamlesh, Lyons, Ronan A, Kee, Frank, Sheikh, Aziz, Rahman, Shamim, Valabhji, Jonathan, Harrison, Ewen M, Sellen, Peter, Haq, Nazmus, Semple, Malcolm G, Johnson, Peter W M, Hayward, Andrew, Nguyen-Van-Tam, Jonathan S

“…To derive and validate risk prediction algorithms to estimate the risk of covid-19 related mortality and hospital admission in UK adults after one or two doses…”
Get more information

Gene-expression profiling of bortezomib added to standard chemoimmunotherapy for diffuse large B-cell lymphoma (REMoDL-B): an open-label, randomised, phase 3 trial by Davies, Andrew, Cummin, Thomas E, Barrans, Sharon, Maishman, Tom, Mamot, Christoph, Novak, Urban, Caddy, Josh, Stanton, Louise, Kazmi-Stokes, Shamim, McMillan, Andrew, Fields, Paul, Pocock, Christopher, Collins, Graham P, Stephens, Richard, Cucco, Francesco, Clipson, Alexandra, Sha, Chulin, Tooze, Reuben, Care, Matthew A, Griffiths, Gareth, Du, Ming-Qing, Westhead, David R, Burton, Catherine, Johnson, Peter W M

“…Biologically distinct subtypes of diffuse large B-cell lymphoma can be identified using gene-expression analysis to determine their cell of origin,…”
Get full text

Molecular High-Grade B-Cell Lymphoma: Defining a Poor-Risk Group That Requires Different Approaches to Therapy by Sha, Chulin, Barrans, Sharon, Cucco, Francesco, Bentley, Michael A, Care, Matthew A, Cummin, Thomas, Kennedy, Hannah, Thompson, Joe S, Uddin, Rahman, Worrillow, Lisa, Chalkley, Rebecca, van Hoppe, Moniek, Ahmed, Sophia, Maishman, Tom, Caddy, Josh, Schuh, Anna, Mamot, Christoph, Burton, Catherine, Tooze, Reuben, Davies, Andrew, Du, Ming-Qing, Johnson, Peter W M, Westhead, David R

“…Biologic heterogeneity is a feature of diffuse large B-cell lymphoma (DLBCL), and the existence of a subgroup with poor prognosis and phenotypic proximity to…”
Get full text

Phase I Study of the Novel Enhancer of Zeste Homolog 2 (EZH2) Inhibitor GSK2816126 in Patients with Advanced Hematologic and Solid Tumors by Yap, Timothy A, Winter, Jane N, Giulino-Roth, Lisa, Longley, Jemma, Lopez, Juanita, Michot, Jean-Marie, Leonard, John P, Ribrag, Vincent, McCabe, Michael T, Creasy, Caretha L, Stern, Melissa, Pene Dumitrescu, Teodora, Wang, Xiaowei, Frey, Steve, Carver, Jennifer, Horner, Thierry, Oh, Choon, Khaled, Ahmed, Dhar, Arindam, Johnson, Peter W M

“…Enhancer of zeste homolog 2 (EZH2) activity is dysregulated in many cancers. This phase I study determined the safety, maximum-tolerated dose (MTD),…”
Get full text